DOI: 10.12890/2023_004195
Peculiarity of autoimmune hepatitis triggered by SARS-CoV-2 infection
Authors
antonella.gallo@policlinicogemelli.it
Keywords
Acute hepatitis, COVID-19, autoimmunityAbstract
Introduction: Recently, medical interest has been growing in SARS-CoV-2 infection and its multiorgan involvement, including the liver. Up until now, a few reports have described autoimmune hepatitis (AIH) triggered by SARS-CoV-2 infection, but no data are available about the specific liver inflammatory infiltrate and cluster of differentiation. We report a case of AIH triggered by SARS-CoV-2 infection, with a particular focus on its histological and mainly immunohistochemical features.
Case description: A 60-year-old man, with a history of paucisymptomatic SARS-CoV-2 infection that occurred one month earlier, was admitted for alterations of hepatocellular necrosis and cholestasis indexes. He completed vaccination for SARS-CoV-2 a year earlier. The serologies for hepatotropic viruses were negative. The anti- smooth muscle antibodies (ASMA) and antinuclear antibodies (ANA) results were positive. Anti-liver kidney microsome (anti-LKM) antibodies and antimitochondrial (AMA) were negative. By liver biopsy, haematoxylin-eosin staining highlighted severe portal inflammation with a rich CD38+ plasma cell component, while immunohistochemical staining showed low cell CD4+ count and prevalence of CD8+ and CD3+. After biopsy, the patient started an immunosuppressant regimen, with benefit.
Discussion: We can conclude that the patient developed a type 1 AIH triggered by SARS-CoV-2 infection. The presence of CD8 T-cells at immunohistochemical examination suggests different mechanisms from classic AIH. Similar cases are described after AIH triggered by SARS-CoV-2 vaccination.
Conclusion: The AIH after SARS-CoV-2 infection developed by the patient showed a histological picture similar to a classic AIH for the abundant presence of plasma cells, and immunohistochemical features similar to those described after SARS-CoV-2-vaccination.
References
- Napodano C, Pocino K, Stefanile A, Marino M, Miele L, Gulli F et al. COVID-19 and hepatic involvement: the liver as a main actor of the pandemic novel. Scand J Immunol 2021;93:e12977.
- Sucher E, Sucher R, Gradistanac T, Brandacher G, Schneeberger S, Berg T. Autoimmune hepatitis-immunologically triggered liver pathogenesis-diagnostic and therapeutic strategies. J Immunol Res 2019;2019:9437043.
- Boettler T, Csernalabics B, Salié H, Luxenburger H, Wischer L, Salimi Alizei E, et al. SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis. J Hepatol 2022;77:653–659.
- Lee SK, Kwon JH, Yoon N, Lee SH, Sung PS. Immune-mediated liver injury represented as overlap syndrome after SARS-CoV-2 vaccination. J Hepatol 2022;77:1209–1211.
- Li H, Guan Y, Han C, Zhang Y, Liu Q, Wei W, et al. The pathogenesis, models and therapeutic advances of primary biliary cholangitis. Biomed Pharmacother 2021;140:111754.
- Manns MP. Viruses and autoimmune liver disease. Intervirology 1993;35:108–115.
